HERITAGE

Omega Pharma acquires Arterin

Omega Pharma buys Etixx

Omega Pharma acquires OTC-brands of GSK Europe

Delisting of Omega Pharma from NYSE/Euronext

Acquisition of Laboratoire de la Mer, a world leader in natural Cough & Cold products

Formation of the 50/50 joint venture with Modi-Mundipharma Group in India

Sale of 24% stake in Arseus

Various smaller acquisitions, including Aurora (Australia, New Zealand, Singapore), Interdelta (Switzerland), Altermed (Czech Republic and Slovakia), O+A Pharma (Hungary), Hipocrate (Romania), Fishem (Turkey), and Cinetic Laboratories (Argentina)

Arseus carve-out via separate IPO

Inclusion of Silence in the brand portfolio through the acquisition of Persee Médica

Expansion into CEE and CIS through the acquisition of Bittner Pharma

Acquisition of Wartner Europe

Acquisition of 60 OTC brands from Pfizer which both expanded existing activities and provided access to new European countries such as Italy, Ireland, Scandinavia and Switzerland

Expansion into Italy and Scandinavia via acquisitions

Expansion into Greece

Introduction in the Bel 20 index and expansion into Portugal

Expansion into France through the acquisition of Pharmygiène

Acquisition of Chefaro (AkzoNobel OTC) with operations in UK, Spain, Germany and The Netherlands

Start of the internationalization process

Start of the acquisition process on the Belgian home market

IPO on Euronext Brussels

Management buy-out by Marc Coucke

Omega Pharma is created by two pharmacists, including Marc Coucke, the current CEO. With the slogan 'By pharmacists, for pharmacists' the founders of the Company began to build a Consumer Health organization in which the relationship with pharmacists plays a central role